[HTML][HTML] Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of> 72 400 specimens

EA Sugarman, N Nagan, H Zhu, VR Akmaev… - European journal of …, 2012 - nature.com
EA Sugarman, N Nagan, H Zhu, VR Akmaev, Z Zhou, EM Rohlfs, K Flynn, BC Hendrickson…
European journal of human genetics, 2012nature.com
Spinal muscular atrophy (SMA) is a leading inherited cause of infant death with a reported
incidence of∼ 1 in 10 000 live births and is second to cystic fibrosis as a common, life-
shortening autosomal recessive disorder. The American College of Medical Genetics has
recommended population carrier screening for SMA, regardless of race or ethnicity, to
facilitate informed reproductive options, although other organizations have cited the need for
additional large-scale studies before widespread implementation. We report our data from …
Abstract
Spinal muscular atrophy (SMA) is a leading inherited cause of infant death with a reported incidence of∼ 1 in 10 000 live births and is second to cystic fibrosis as a common, life-shortening autosomal recessive disorder. The American College of Medical Genetics has recommended population carrier screening for SMA, regardless of race or ethnicity, to facilitate informed reproductive options, although other organizations have cited the need for additional large-scale studies before widespread implementation. We report our data from carrier testing (n= 72 453) and prenatal diagnosis (n= 121) for this condition. Our analysis of large-scale population carrier screening data (n= 68 471) demonstrates the technical feasibility of high throughput testing and provides mutation carrier and allele frequencies at a level of accuracy afforded by large data sets. In our United States pan-ethnic population, the calculated a priori carrier frequency of SMA is 1/54 with a detection rate of 91.2%, and the pan-ethnic disease incidence is calculated to be 1/11 000. Carrier frequency and detection rates provided for six major ethnic groups in the United States range from 1/47 and 94.8% in the Caucasian population to 1/72 and 70.5% in the African American population, respectively. This collective experience can be utilized to facilitate accurate pre-and post-test counseling in the settings of carrier screening and prenatal diagnosis for SMA.
nature.com